Telephone
61.8.6558.0886
Address
Level 3 101 St George’s Terrace Perth, Western Australia (WA) 6000
Description
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.9 - 3.35
Trade Value (12mth)
AU$7,823.00
1 week
-7.84%
1 month
-1.05%
YTD
-6%
1 year
-11.32%
All time high
20453.1
EPS 3 yr Growth
-61.800%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-21.40%
ROIC
-16.50%
Interest Coverage
-89.60
Quick Ratio
0.10
Shares on Issue (Fully Dilluted)
11m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
September 2023 Quarterly Activities Report
×
September 2023 Quarterly Activities Report |
31 October 23 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
31 October 22 |
September 2022 Quarterly Activities Report
×
September 2022 Quarterly Activities Report |
31 October 22 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
31 October 06 |
Gleneagle Gold Limited - Annual Report
×
Gleneagle Gold Limited - Annual Report |
31 May 23 |
Zeliras diabetic nerve pain drug outperforms Lyrica
×
Zeliras diabetic nerve pain drug outperforms Lyrica |
31 May 23 |
Investor Webinar - Top line trial results
×
Investor Webinar - Top line trial results |
31 May 23 |
Top Line Results Investor Presentation
×
Top Line Results Investor Presentation |
31 May 23 |
Zelira Non-Executive Director Appointed
×
Zelira Non-Executive Director Appointed |
31 May 23 |
Proposed issue of securities - ZLD
×
Proposed issue of securities - ZLD |
31 July 23 |
June 2023 Quarterly Activities Report
×
June 2023 Quarterly Activities Report |
31 July 23 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
31 January 23 |
December 2022 Quarterly Activities Report
×
December 2022 Quarterly Activities Report |
31 January 23 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
31 January 22 |
December 2021 Quarterly Activities Report
×
December 2021 Quarterly Activities Report |
31 January 22 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
31 January 22 |
Board Changes
×
Board Changes |
31 January 22 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
31 January 22 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
31 August 23 |
Preliminary Final Report
×
Preliminary Final Report |
31 August 22 |
Appendix 4E and Financial Report to Shareholders
×
Appendix 4E and Financial Report to Shareholders |
31 August 22 |
Appendix 4G
×
Appendix 4G |
31 August 22 |
Zelira Full Year Results
×
Zelira Full Year Results |
30 September 22 |
Notification of cessation of securities - ZLD
×
Notification of cessation of securities - ZLD |
30 September 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 10 |
Annual Report (GLN-AU)
×
Annual Report (GLN-AU) |
30 November 18 |
Annual General Meeting Presentation 2018
×
Annual General Meeting Presentation 2018 |
30 May 22 |
ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
×
ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.